At the 2019 Conference on Retroviruses and Opportunistic Infections (CROI), researchers announce the second cure of a person with HIV. Like the 2007 case of the “Berlin Patient” (the first person to be cured of HIV), the “London Patient” has no detectable HIV infection three years after he received a bone marrow transplant from a donor who is genetically immune to HIV, despite having been off antiretroviral therapy (ART) for 18 months. Both patients received bone marrow transplants to treat cancer. While the treatment is too dangerous and costly for widespread use, researchers hail the news as further proof that HIV can be cured.
NIH announces the launch of a clinical trial to evaluate long-acting ART for maintaining HIV suppression in people who find it a challenge to take daily ART in pill form. The study, called Long-Acting Therapy to Improve Treatment Success in Daily Life, or LATITUDE, will help determine whether a combination of two experimental injectable formulations of ART are better than conventional daily medications in managing HIV infection in this population.